A bioscaffold comprising a graphene matrix for use in cellular therapy is disclosed. In particular, a bioscaffold having a coating of dexamethasone on a three-dimensional graphene matrix is provided, wherein the bioscaffold elutes dexamethasone to reduce inflammatory responses following implantation of the bioscaffold in a subject. Having the dexamethasone released locally in the vicinity of the bioscaffold avoids the systemic side effects from conventional intravenous delivery while allowing the dexamethasone to modulate the inflammatory milieu within the transplantation microenvironment.

A bioscaffold comprising a graphene matrix for use in cellular therapy is disclosed. In particular, a bioscaffold having a coating of dexamethasone on a three-dimensional graphene matrix is provided, wherein the bioscaffold elutes dexamethasone to reduce inflammatory responses following implantation of the bioscaffold in a subject. Having the dexamethasone released locally in the vicinity of the bioscaffold avoids the systemic side effects from conventional intravenous delivery while allowing the dexamethasone to modulate the inflammatory milieu within the transplantation microenvironment.

Provided herein are compositions and methods for treating bone fractures. In particular, provided herein are systems comprising carbon fiber sleeves and biocompatible polymers and the use of such systems in treating or preventing bone fractures.

A method of producing a multi-layered functionalised graphene oxide paper, comprises the steps of providing an aqueous suspension of oxidised graphene oxide flakes, size reducing the oxidised graphene oxide flakes in the suspension to provide an aqueous suspension of particulate oxidised graphene oxide having an average particle size of less than 1 μm and drying the aqueous suspension in a vessel to provide a multi-layered graphene oxide material. The multi-layered graphene oxide material is annealed to provide a multi-layered reduced graphene oxide material, before surface grafting functional groups to the surface of the multi-layered reduced graphene oxide material by reacting the material with a functional group precursor in the presence of plasma. The use of a graphene oxide material to treat bone defects, and as an energy storage device, is also described.

A method of producing a multi-layered functionalised graphene oxide paper, comprises the steps of providing an aqueous suspension of oxidised graphene oxide flakes, size reducing the oxidised graphene oxide flakes in the suspension to provide an aqueous suspension of particulate oxidised graphene oxide having an average particle size of less than 1 μm and drying the aqueous suspension in a vessel to provide a multi-layered graphene oxide material. The multi-layered graphene oxide material is annealed to provide a multi-layered reduced graphene oxide material, before surface grafting functional groups to the surface of the multi-layered reduced graphene oxide material by reacting the material with a functional group precursor in the presence of plasma. The use of a graphene oxide material to treat bone defects, and as an energy storage device, is also described.

An implant and/or an implant component is made available, having a main body which, at least on a surface, contains or consists of an electrically conductive material, and having a layer of calcium hydroxide applied to the electrically conductive material of the main body. The implant or the implant component is characterized in that the layer of calcium hydroxide contains calcium phosphate, specifically in a percentage by weight that is less than the percentage by weight of calcium hydroxide in this layer. A method for making available the implant according to the invention or the implant component according to the invention is also proposed. The implant made available and the implant component made available are characterized in that they have a local and temporary antimicrobial action, prevent formation of antibiotic-resistant microorganisms, act on bone substance in a manner that promotes growth, and produce no adverse side effects in the body.

Pure compressed diamond (PCD), grown in a laboratory, is laser-shaped into dental implants with high tensile strength, high compressive strength, high thermal conductivity, and which are harder than any other substance on earth. PCD is harder than ceramic zirconia and harder than titanium. Because PCD is pure carbon, it is also 100% compatible with carbon-based living tissue. Unlike titanium, it does not provoke an immune response. PCD implants readily integrate into human jawbone. This drastically reduces post-surgery bone loss.

A method of forming an immunomodulatory implant operatively arranged to chemotactically facilitate bone morphogenesis, the method including forming a matrix of a first material, the matrix including an outer surface, and a plurality of pores, and applying an antigen to the matrix, wherein the antigen including at least one of a bacterial antigen or a viral antigen.

A method of forming an immunomodulatory implant operatively arranged to chemotactically facilitate bone morphogenesis, the method including forming a matrix of a first material, the matrix including an outer surface, and a plurality of pores, and applying an antigen to the matrix, wherein the antigen including at least one of a bacterial antigen or a viral antigen.

A method for preparing a conductive biomimetic skin scaffold material with self-repairing function includes the following steps: adding 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to a homogeneous dispersion of acidified carbon nanotubes, poly(3,4-ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS), and gelatin to cross-link to obtain a conductive composite colloid; and injecting the conductive composite colloid into a mold, aging at −4-4° C. for 12-24 hours, and then soaking in a phosphate-buffered saline (PBS) solution with a pH of 7.0-7.4 for 12-24 hours to obtain the conductive biomimetic skin scaffold material.